Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress : vimarsana.com

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...

Related Keywords

Australia , United States , United Kingdom , Israel , Singapore , China , Boston , Massachusetts , Sadal , Kyongsang Bukto , South Korea , American , Richard Paulson , Reshma Rangwala , Michael Kauffman , Sharon Shacham , Selective Inhibitor Of Nuclear Export , American Society Of Clinical Oncology , Linkedin , Nasdaq , European Society Of Medical Oncology Virtual Plenary , Karyopharm Selective Inhibitor Of Nuclear Export , Menarini Group , Promedico Ltd , Committee For Medicinal Products Human Use , Information Department , Karyopharm Therapeutics Inc , Society For Gynecologic Oncology , Drug Administration , European Commission , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , Healthcare Royalty Management , Antengene Therapeutics , Achieved First Quarter , Versus First Quarter , License Revenues , Net Product Revenue , Preliminary Data , Evaluating Selinexor , Promising Results , Pre Specified Exploratory Subgroup Analysis , Type Endometrial Cancer , Recent Approvals Received , Partner Antengene Continues , Conference Call Scheduled , Chief Executive Officer , Antengene Therapeutics Limited , Mainland China , American Society , Clinical Oncology , European Society , Medical Oncology , Virtual Plenary , Gynecologic Oncology , Medicinal Products , Human Use , Chief Medical , Chief Scientific Officer , Senior Clinical Advisor , Scientific Advisory Board , Revenue Interest Agreement , Karyopharm Therapeutics , Selective Inhibitor , Nuclear Export , Medical Information , Fetal Toxicity , Private Securities Litigation Reform Act , Annual Report , Karyopharm Therapeutics Inc ,